Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents following successful PCI in non-ST-elevation myocardial infarction: Findings from the guthrie health off-label stenT (GHOST) registry

Journal of Interventional Cardiology

Volumn 25, Issue 1, 2012, Pages 28-36

  Harjai, Kishore J ^a   Sattur, Sudhakar ^a   Orshaw, Pamela ^a   Boura, Judy ^a  

^a GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; PACLITAXEL; RAPAMYCIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEATH; DEVICE SAFETY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DRUG-ELUTING STENTS; ELECTROCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PENNSYLVANIA; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84857651226     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2011.00677.x     Document Type: Article

References (28)

1. Anderson JL, Adams CD, Antman EM, et al,. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50 (7): e1-e157.
2. Kandzari DE, Roe MT, Ohman EM, et al,. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2005; 96 (6): 750-755. (Pubitemid 41317641)
3. Moses JW, Mehran R, Nikolsky E, et al,. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: Analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45 (8): 1165-1171. (Pubitemid 40523132)
4. Mauri L, Silbaugh TS, Garg P, et al,. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 2008; 359 (13): 1330-1342.
5. Kirtane AJ, Gupta A, Moses JW, et al,. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
6. Beattie MJ, Lee MS,. Safety and efficacy of drug-eluting stents compared with bare metal stents in ST-elevation myocardial infarction. Rev Cardiovasc Med. 2010; 11 (2): c57-c73.
7. Brar SS, Leon MB, Stone GW, et al,. Use of drug-eluting stents in acute myocardial infarction: A systematic review and meta-analysis. J Am Coll Cardiol 2009; 53 (18): 1677-1689.
8. James SK, Stenestrand U, Lindback J, et al,. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009; 360 (19): 1933-1945.
9. Mauri L, Hsieh WH, Massaro JM, et al,. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356 (10): 1020-1029. (Pubitemid 46376802)
10. Stenestrand U, James K, Lindback J, et al,. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: Long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2010; 31 (2): 177-186.
11. Stettler C, Wandel S, Allemann S, et al,. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948. (Pubitemid 47393576)
12. Tu JV, Boven J, Chiu M, et al,. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007; 357 (14): 1393-1402. (Pubitemid 47541971)
13. Hill ME, Rosenwaike I,. The Social Security Administration's Death Master File: The completeness of death reporting at older ages. Soc Secur Bull 2001; 64 (1): 45-51.
14. Cutlip DE, Windecker S, Mehran R, et al,. Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115 (17): 2344-2351. (Pubitemid 46685903)
15. Harjai KJ, Shenoy C, Orshaw P, et al,. Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention. Insights from the Guthrie PCI Registry. Heart 2009; 95 (19): 1579-1586.
16. Morice MC, Serruys PW, Sousa JE, et al,. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780. (Pubitemid 34586912)
17. Moses JW, Leon MB, Popma JJ, et al,. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323. (Pubitemid 37186209)
18. Stone GW, Ellis SG, Cox DA, et al,. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231. (Pubitemid 38067635)
19. Harjai KJ, Orshaw P, Shenoy C, et al,. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials. Findings from the ghost study (Guthrie Health System Off-Label Stent Study). J Interv Cardiol 2008; 21 (4): 315-324. (Pubitemid 352033300)
20. Liebson Pr, Klein LW,. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39 (5): 399-444. (Pubitemid 27147269)
21. Kerensky RA, Wade M, Deedwane P, et al,. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 2002; 39 (9): 1456-1463. (Pubitemid 34439060)
22. Wong, GC, Morrow DA, Murphy S, et al,. Elevations in troponin T and I are associated with abnormal tissue level perfusion: A TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002; 106 (2): 202-207.
23. Mizuno K, Satomura K, Miyamoto A, et al,. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326 (5): 287-291.
24. Jang IK, Gold HK, Ziskind AA, et al,. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79 (4): 920-928. (Pubitemid 19100552)
25. Goldstein JA, Demetriou D, Grines CL, et al,. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915-922.
26. Luscher TF, Steffel J, Eberli FR, et al,. Drug eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation 2007; 115: 1051-1058. (Pubitemid 46328299)
27. Joner M, Finn AV, Farb A, et al,. Pathology of drug-eluting stents in humans delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202. (Pubitemid 43929240)
28. Grines CL, Bonow R, Casey DE, et al,. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115 (6): 813-818. (Pubitemid 46294748)